What is Shift Labs?
Shift Labs is a specialized medical technology firm recognized for developing the DripAssist Infusion Rate Monitoring Platform. As the first FDA-cleared monitor specifically engineered for gravity-fed intravenous infusions, the company addresses a critical gap in patient safety and operational efficiency. By providing real-time, accurate data for infusion therapy, Shift Labs enables healthcare providers in home care, veterinary medicine, and public health sectors to optimize medication delivery. The platform effectively bridges the gap between expensive, complex infusion pumps and manual monitoring, offering a scalable solution that reduces overhead while maintaining rigorous clinical standards.
How much funding has Shift Labs raised?
Shift Labs has raised a total of $1.3M across 2 funding rounds:
Unspecified
$1.2M
Debt
$96K
Unspecified (2015): $1.2M, investors not publicly disclosed
Debt (2021): $96K led by PPP
Key Investors in Shift Labs
Undisclosed Investor
An institutional partner providing foundational capital to support early-stage medical device development.
PPP
Public-Private Partnership
What's next for Shift Labs?
With the recent influx of capital, Shift Labs is poised to accelerate its market penetration and broaden its product ecosystem. The strategic focus will likely shift toward enhancing the digital integration of the DripAssist platform, potentially incorporating advanced analytics to further streamline home-based care workflows. As the company transitions from its initial development phase into a period of sustained enterprise-level growth, the emphasis will remain on securing broader clinical adoption and exploring new therapeutic applications for its monitoring technology. This trajectory suggests a robust outlook for the firm as it continues to redefine the economics of infusion therapy.
See full Shift Labs company page
